BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31444238)

  • 21. Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
    Hudelist G; Wülfing P; Kersting C; Burger H; Mattsson B; Czerwenka K; Kubista E; Gschwantler-Kaulich D; Fink-Retter A; Singer CF
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):67-73. PubMed ID: 17661084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
    Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
    Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
    Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
    Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
    Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
    Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
    Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
    Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Zeng Y; Gao W; Chen X; Shen K
    Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
    Mardekian SK; Bombonati A; Palazzo JP
    Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
    Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
    Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.
    Miligy IM; Toss MS; Gorringe KL; Lee AHS; Ellis IO; Green AR; Rakha EA
    Br J Cancer; 2019 May; 120(11):1075-1082. PubMed ID: 31065110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis.
    Lah TT; Kalman E; Najjar D; Gorodetsky E; Brennan P; Somers R; Daskal I
    Hum Pathol; 2000 Feb; 31(2):149-60. PubMed ID: 10685628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.
    Knudsen ES; Dervishaj O; Kleer CG; Pajak T; Schwartz GF; Witkiewicz AK
    Cell Cycle; 2013 Jul; 12(13):2042-50. PubMed ID: 23759596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.
    Toss MS; Miligy I; Al-Kawaz A; Alsleem M; Khout H; Rida PC; Aneja R; Green AR; Ellis IO; Rakha EA
    Mod Pathol; 2018 Aug; 31(8):1226-1236. PubMed ID: 29559742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
    Vogl G; Dietze O; Hauser-Kronberger C
    Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.
    Rice AJ; Steward MA; Quinn CM
    J Clin Pathol; 2002 Dec; 55(12):921-5. PubMed ID: 12461058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-Acetylglucosaminyltransferase III (GnT-III) but not N-Acetylgalactosaminyltransferase-6 and 8 are Differentially Expressed in Invasive and In Situ Ductal Carcinoma of the Breast.
    da Silva Filho AF; Vieira-de-Mello GS; Dos Santos PB; de Melo Rêgo MJB; Ribeiro-Silva A; Beltrão EIC
    Pathol Oncol Res; 2019 Apr; 25(2):759-768. PubMed ID: 30689164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
    BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.